BIA Separations Inc.’s Post

Join in later today and learn more about optimizing lentiviral purification and see some Leprechaun data! #LVV #genetherapy

🎉 We are thrilled to announce that Virica has won the best abstract award for ISCT! Biomanufacturing of cell and gene therapies is complex and hampered by variability in yield, quality, and scalability. 💡 At Virica, we rapidly optimize viral vector production by combining the power of our high-throughput virology platform with the statistical prowess of DoE (design of experiments). The outcome? ✅ Achieve rapid optimization of multiple factors in viral vector production process in time frames not achievable through the traditional one-factor-at-a-time (OFAT) strategy. ✅ Our users save time, resources, and effort while gaining flexibility and a deeper understanding of their production parameters on output variables. Visit our website for more information: https://lnkd.in/e3zvChi How are you tackling the complexity of cell and gene therapy manufacturing? Drop it in the comments below! #ISCT2024 #DoE #Biomanufacturing

📣 We are kicking off the fall conference season with BPI Boston! Looking to drive up batch productivity and drive down manufacturing COGS? Here are two ways our Viral Sensitizers (VSEᵀᴹ) cell enhancers can tackle the challenge of innate cellular defenses during cell and gene therapy (CGT) production: ✔ A tailored formulation of VSEs optimized for your platform, cell substrate and viral product.   ✔ Achieve higher yields and improved quality - validated in 50+ applications across cell lines and viral products. 💡 Unlock the potential of your production platform with our VSEs and Design of Experiments (DoE) expertise to optimize viral vector production and boost viral yields rapidly. 🤝 If you are attending, swing by booth #1811! We'd love to chat! Check out our technology: https://lnkd.in/gu2m3RcX #biomanufacturing #BPIBoston #innovation #biotechnology

🌍 Yesterday was World #CRISPR Day, the Nobel-prize winning gene editing technique which is revolutionizing the treatment of genetic conditions. We believe in a world where vision-saving treatments for blinding diseases are a reality for all, as a part of our ongoing strategic collaboration with Intellia Therapeutics, Inc. to develop novel treatments utilizing their CRISPR-based gene editing technologies. 🤝 Find out more about what we do with CRISPR here: 🔗 https://lnkd.in/eM5mAx36 #Ophthalmology #GenomicMedicines 👁️

𝗗𝗶𝗱 𝗬𝗼𝘂 𝗞𝗻𝗼𝘄? rcAAV assays are capable of detecting even a single replication-competent virus particle in a large batch of AAV vectors. 🧬This ultra-sensitive detection is 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 for preventing potential complications in patients receiving gene therapy, ensuring that every treatment is as safe and effective as possible. 𝗥𝗲𝗮𝗱𝘆 𝘁𝗼 𝗱𝗶𝘃𝗲 𝗱𝗲𝗲𝗽𝗲𝗿 𝗶𝗻𝘁𝗼 𝗵𝗼𝘄 𝘄𝗲 𝗰𝗮𝗻 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝘆𝗼𝘂𝗿 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝘀? Download our latest white paper, 𝘈𝘥𝘢𝘱𝘵𝘪𝘯𝘨 𝘢 𝘳𝘤𝘈𝘈𝘝 𝘈𝘴𝘴𝘢𝘺 𝘧𝘰𝘳 𝘊𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘔𝘢𝘯𝘶𝘧𝘢𝘤𝘵𝘶𝘳𝘪𝘯𝘨, to learn more about our innovative approaches and how we’re setting new standards in the industry. Download here: https://lnkd.in/e6WcPmzz   Partner with SK pharmteco to achieve your gene therapy goals with the peace of mind that comes from knowing your vectors are rigorously tested and safe. Together, we can push the boundaries of innovation and deliver life-changing therapies to those who need them most. #TestingTuesday #AnalyticalServices #rcAAV #ViralVector #CDMO #GeneTherapy

In a recent study, researchers have developed the SGMO Helper, a baculovirus-based insect cell production system for manufacturing adeno-associated viruses (AAV) used in gene and cell therapy. It offers enhanced flexibility in modulating Rep and Cap protein expression levels. Incorporating modifications to the AAV6 capsid sequence improves yield, capsid integrity, and potency, resulting in improved production compared to traditional methods like Bac-RepCap. Next-generation sequencing analysis confirms stability over six passages, and scalable production in bioreactors enhances yield and potency, making the SGMO Helper an advanced platform for AAV manufacturing, crucial for cutting-edge gene and cell therapies. #GeneTherapy #CellTherapy #AAVProduction #BioreactorScaleup #NextGenSequencing #InsectCellSystems #BaculovirusExpression #AAV6Improvements #TherapeuticViruses #MedicalResearch https://lnkd.in/eCSyZT2S

🔬 Early-Phase Testing Support: From Discovery to the Clinic 🧬 At #DINAMIQS, we recognize that while the genome and capsid are closely linked, it’s precision in #genomeengineering that truly unlocks the full therapeutic potential of gene therapies. Our science-driven approach goes beyond just the vector—we’re here to help you harness the full power of your gene therapy programs. Recent conversations point to growing demand for more tailored solutions during early-phase testing: #constructdesign, #optimization, #feasibility, and #DOE studies. With the capability of performing small-scale runs (starting at 0.5L) to help you quickly assess and select your top asset(s) for clinical advancement and future #scalablemanufacturing, we provide these tailored early-phase solutions that others may not—because we know expertise and adaptability are key to your success. #GeneTherapy #ViralVector #AAV #Lenti #EarlyPhaseTesting #Biotech #Innovation #Optimization #Commercialization

Boosting AAV Productivity through Innovation! Join Virica Biotech and REITHERA on Thursday, 24th at 11 AM at Booth B14/16 at #ESGCT2024 to discover the latest insights on increasing AAV production. 🚀. Learn how; 🔹 Virica’s Viral Sensitizer (VSE™) platform enhances viral yields by reducing cellular defenses during AAV production. 🔹 ReiThera’s proprietary clonal cell line, ReiCell–AAVx, optimized for high-density suspension growth. 🔹 ReiThera uses Virica’s cell enhancers in combination with their ReiCell–AAVx cell line with a presentation of their latest data. Together, these innovations have the potential to enhance AAV titers across multiple serotypes. Don’t miss this opportunity to learn how combining these technologies can drive your gene therapy projects forward! #AAV #GeneTherapy #Biotech #LifeSciences #ViricaBiotech #Innovation

At Infirmacea, we're pioneering a fat-directed #DNAtherapy - a safe and cost-effective approach to #genetherapy. By injecting DNA into subcutaneous fat, we transform this tissue into a “health engine” that can boost disease resistance. Since fat is both abundant and easily accessible for injection, it presents an ideal target for gene therapy, making our method highly efficient and practical. One of the key challenges in this field has been efficiently transfecting fat cells, terminally differentiated ones, without using viral vectors. We’ve overcome this with our revolutionary technology, #gBoost, a cell-selective gene expression enhancer, enabling effective non-viral delivery and opening new possibilities for advanced gene therapies.

Book your free seat to this upcoming live webinar titled Downstream Platform Process Development for AAV viral vectors; Challenges and Opportunities On 2nd October 2024 | 10:00am EDT / 7:00am PDT / 3:00pm BST / 4:00pm CEST This talk is designed for professionals and researchers from the scientific community, particularly those engaged in industry applications. In this session, I will delve into the concept of platformability in the context of AAV downstream processes. I will examine the opportunities this approach offers for enhancing efficiency, scalability, and reproducibility in viral vector production. Key topics will include: – Defining Platformability: Understanding its significance in streamlining AAV production. Technological Opportunities: Innovative methods and tools available for optimizing downstream processes. Challenges and Solutions: Identifying common obstacles and discussing potential strategies to overcome them. Attendees will gain valuable insights into the latest advancements and practical solutions for developing robust downstream processes, positioning them at the forefront of AAV vector production technology. Presented by Parag Kumthekar, Lead Gene Therapy Downstream Process Development at UCB https://lnkd.in/eVj-4zqw #AAV #downstreamprocessing #aavproduction #aavviralvectors #cmcdevelopment #genetherapy #processdevelopment